Evidence map›Paper›PMID 26439809›Full record

ReviewRegenerative medicine2015

Induced pluripotent stem cells for cardiovascular disease: from product-focused disease modeling to process-focused disease discovery.

Katherine A Campbell, Andre Terzic, Timothy J Nelson

Abstract readReview
In one paragraph

Review in Regenerative medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Identification of an IScientific reports · 2018
    Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Katherine A CampbellDepartment of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.
Andre TerzicDepartment of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.
Timothy J NelsonDepartment of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.

Funding

Predoctoral Training Program in Molecular PharmacologyT32GM072474 · NIGMS · MAYO CLINIC ROCHESTER · PI KARNITZ, LARRY M · 2005 to 2020
$2.4M
Dysfunctional regeneration in cardiomyopathy: iPS-based diagnosis and therapyDP2OD007015 · OD · MAYO CLINIC ROCHESTER · PI NELSON, TIMOTHY JAMES · 2010 to 2010
$2.4M
NIGMS NIH HHS T32 GM072474NIH HHS DP2 OD007015
6 · The paper itself

Abstract

Induced pluripotent stem (iPS) cell technology offers an unprecedented opportunity to study patient-specific disease. This biotechnology platform enables recapitulation of individualized disease signatures in a dish through differentiation of patient-derived iPS cells. Beyond disease modeling, the in vitro process of differentiation toward genuine patient tissue offers a blueprint to inform disease etiology and molecular pathogenesis. Here, we highlight recent advances in patient-specific cardiac disease modeling and outline the future promise of iPS cell-based disease discovery applications.

Indexed as

AnimalsBiotechnologyCardiovascular DiseasesCell DifferentiationCellular ReprogrammingDisease Models, AnimalHumansInduced Pluripotent Stem CellsPhenotypeRegenerative MedicineTissue Engineeringcardiomyocytecardiomyopathychannelopathydisease discoverydisease modelingdisease pathogenesisinduced pluripotent-stem cellregenerative medicine

Identifiers

PMID26439809
PMCPMC4747237

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.